You are here: Industry Insights > Xiidra

News List

Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio worldpharmanews
July 02, 2019
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio.
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care worldpharmanews
May 15, 2019
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care.
Novartis to buy Takeda’s dry eye drug Xiidra for $3.4bn pharmaceutical-business-review
May 14, 2019
Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn.
Novartis to Acquire Xiidra® americanpharmaceuticalreview
May 10, 2019
Novartis to Acquire Xiidra®
Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal fiercepharma
May 09, 2019
Takeda is looking to lighten the huge debt burden from the Shire buyout. Novartis wants to beef up its eye medicine portfolio after the Alcon spinoff. Now, the two companies have found a deal where their needs align.
Novartis to acquire Takeda's dry eye treatment Xiidra in a deal valued at up to $5.3 billion firstwordpharma
May 09, 2019
Novartis on Wednesday announced that it has reached an agreement to purchase the assets associated with Takeda's dry eye treatment Xiidra (lifitegrast). In the deal,
Shire files dry-eye drug lifitegrast for marketing approval pharmafile
August 16, 2017
Shire has announced that it has submitted its dry-eye drug for European marketing approval, a year after it had gained approval in the US for the treatment of dry eye disease.